- Home
- JSPR vs SRZN Comparison
JSPR vs SRZN Comparison
Compare JSPR & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | SRZN |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4M | 117.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JSPR | SRZN |
|---|---|---|
| Price | $1.81 | $24.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | $25.60 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 3.8M | 103.9K |
| Earning Date | 11-10-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,604,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.39 | $5.90 |
| 52 Week High | $23.11 | $24.88 |
Technical Indicators
Market Signals| Indicator | JSPR | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 85.00 |
| Support Level | $1.60 | $14.94 |
| Resistance Level | $1.93 | $24.86 |
| Average True Range (ATR) | 0.20 | 1.57 |
| MACD | 0.03 | 0.92 |
| Stochastic Oscillator | 36.90 | 97.12 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).